A large randomised placebo controlled trial among trauma patients with or at risk of significant haemorrhage, of the effects of antifibrinolytic treatment on death and transfusion requirement. CRASH-2 is a randomised, controlled, double-blind trial undertaken in 274 hospitals in 40 countries. A total of 20211 adult trauma patients, with, or at risk of, significant bleeding (haemorrhage) were randomly assigned within 8 hours of injury to either tranexamic acid (TXA) or matching placebo. The primary outcome was death in hospital within four weeks of injury and was described with the following categories: bleeding, vascular occlusion (myocardial infarction, stroke and pulmonary embolism), multiorgan failure, head injury, and other. This dataset is available at https://freebird.lshtm.ac.uk/index.php/data-sharing/downloads/crash2/

The data set includes patient demographics (age, sex), baseline measures (systolic blood pressure, respiratory rate, heart rate, capillary refill time and GCS), time from injury and injury type and primary outcome death in hospital within 4 weeks of injury. Patient status (dependency) at discharge is included as is patient management (days in ICU and surgical operations); complications (vascular occlusion, DVT and bleeding); transfusion status and number of units of red blood cells, fresh frozen plasma, platelets and cryoprecipitates transfused; administration or not of Recombinant Factor viia. The data set is an Excel comma separated value file containing 20208 rows comprising a header row of data field names (variables) and 20207 patient records. Not included are 4 patient records for whom consent was withdrawn. The data set includes 46 data fields (variables) including the unique 6-digit identifier for each patient in the form of a 4 digit (treatment box) number and 2 digit (treatment pack) number. Excluded are site name, site identifier, country and treatment code (i.e. treatment allocation) that may be obtained on direct request.

Tranexamic, Haemorrhage, Trauma